M. D. Anderson Cancer Center's (MDACC) planning and evaluation activities can be grouped into 4 categories: external advisory board (EAB), program reviews, internal planning and review, and program development. External Advisory Board: MDACC has received support from the CCSG to fund an External Advisory Board (EAB) for the past 22 years. In this proposal, funds for planning and evaluation are requested to permit MDACC to continue to convene annually this standing committee of 30 outstanding outside scientific advisors to help plan and evaluate our programs, shared resources and institutional research initiatives. The objectives of the EAB are to: review in-house research programs to evaluate their productivity, excellence, and applicability to institutional goals, identify potential gaps in the scientific activities that might be crucial for development to achieve strategic research objectives, and suggest, at a high level, options to consider for closing these gaps, recommend approaches to develop new research directions, such as the three developing programs described here (Molecular Markers, Molecular Imaging, and Melanoma), and evaluate progress of these new programs, assist in recruiting faculty to the institution by identifying appropriate candidates and evaluating the credentials of applicants for critical programs such as the Trust, evaluate the level of collaboration between basic scientists, clinical scientists, and populationbased investigators and recommend actions to appropriately enhance interactivity between these three areas, and estimate the financial investment necessary for implementation of planned research initiatives. Program Reviews: In addition to the EAB, panels of external peer reviewers are convened to evaluate the quality and progress of selected CCSG programs. We expect to conduct 2-3 reviews annually. Internal Planning and Evaluation: Complementing external reviews are institutional internal research planning and review initiatives. A recent successful internal planning effort was the series of research retreats led by Dr. Mendelsohn during 2006-07 to define major research direction for the next 10 years. Another initiative is the ad hoc program and shared resource reviews conducted by Dr. Bast, VP of translational research and cancer center co-director, Ms. Tektiridis, CCSG executive director, and others as appropriate to the circumstances, to monitor progress in addressing issues identified through external peer reviews, address issues identified in administrative and financial assessments, and to review internal program member and shared resource user feedback. Program Development: Currently, there are three CCSG developing programs, Molecular Markers, Molecular Imaging, and Melanoma, reflective of MDACC's research initiatives in these areas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310866
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$77,489
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477
Liao, Zhongxing; Lee, J Jack; Komaki, Ritsuko et al. (2018) Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36:1813-1822
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113

Showing the most recent 10 out of 12418 publications